Glenmark Pharmaceuticals enters its Q1 FY27 results following a year of portfolio transformation and the achievement of a zero-gross-debt balance sheet. Investors will be focused on whether the company can recover its EBITDA margin toward the 23% target after a softer Q4, alongside updates on the commercial ramp-up of its specialty assets in the US and Europe.
| Results date | July 31, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 37,706 Mn |
| Previous quarter PAT | Rs. 3,013 Mn |
| Previous quarter EBITDA margin | 20.2% |
| Market cap | Rs. 61,858.42 Cr |
| CMP | Rs. 2,192.0 |
The Board will consider the unaudited financial results for the quarter ended June 30, 2026, on July 31, 2026.
The earnings call is scheduled for August 3, 2026, from 8:30 am to 9:30 am IST, with dial-in access provided for India, USA, UK, Singapore, and Hong Kong.
Glenmark's India business is expected to remain a primary growth engine, with the segment likely landing within the management-guided run-rate of Rs. 1,150–1,200 Cr per quarter, supported by a 12.1% YoY IPM growth trend as of May 2026. The US segment faces ongoing pricing pressure in the base generics business, though this is expected to be partially offset by the launch of Olanzapine for Injection and Progesterone Vaginal Inserts 100 mg, alongside a significant FX tailwind from the rupee's ~10.6% YoY depreciation. Management's EBITDA margin trajectory remains the critical watch item; while the Q4 FY26 margin of 20.2% was below the 23% exit target, the company benefits from zero gross debt and operating leverage from its branded specialty portfolio. The upcoming call will likely focus on whether these factors, coupled with the commercial ramp-up of the Monroe facility, can drive a sequential margin recovery toward the 23% threshold.
EBITDA Margin and Revenue Guidance: Monitoring the path back to guided profitability levels.
US Business and Monroe Facility: Assessing the contribution of new launches and manufacturing status.
Innovative Portfolio Milestones: Tracking the progress of Glenmark's specialty assets.
Regulatory and Operational Risks: Monitoring facility compliance and working capital.
Management expects growth to be driven by the Flovent 44 launch and at least two sole First-to-File opportunities in the second half of FY27. Additionally, the commercial ramp-up of the Monroe facility and complex respiratory filings are expected to support expansion.
The company maintains a medium-term growth capex guidance of approximately Rs. 800 Cr annually. Management has confirmed this run-rate is consistent with their ongoing investment requirements.
The Monroe facility received a VAI classification from the U.S. FDA, enabling the restart of commercial manufacturing. Commercial production was expected to commence in Q4 FY26, with the first 1-2 approved products commercialized in the following year.
Management has stated they remain on track to achieve the overall objectives of the Glenmark 3.0 framework. This includes achieving zero gross debt, which was successfully completed as of Q2 FY26.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now